They said it takes 6 months average to turn a lead into a sale if the "lead" sees any benefits. To me that sounds very long as I worked in sales and I worked in a very competitive business environment. But let's take this as the norm for that industry and therefore we should see an increase in sales and revenue reported by the end of this year, meaning reported in January's 4C. If they still can't get more than 20 units sold then either the new management or SOZO is useless / not wanted. That's the simple reality for me.
But there is strong demand, the clinical benefits are documented and certified, no competition and a growing coverage by insurers. How can anyone not increase their sales having that market domination is actually beyond my understanding.
Yes, again I come around as arrogant, but I myself would easily sell 50 SOZOs if the facts about SOZO are true. Just show the insurers the LT savings and explain to the hospitals that they actually make money by testing patients. How hard can that be?
GLTA
- Forums
- ASX - By Stock
- IPD
- Media
IPD
impedimed limited
Add to My Watchlist
7.69%
!
3.6¢

Media, page-208
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
3.6¢ |
Change
-0.003(7.69%) |
Mkt cap ! $72.98M |
Open | High | Low | Value | Volume |
3.7¢ | 3.7¢ | 3.6¢ | $7.151K | 194.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 109660 | 3.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.7¢ | 42471 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9660 | 0.036 |
2 | 390000 | 0.035 |
3 | 338208 | 0.034 |
1 | 638321 | 0.033 |
3 | 459150 | 0.030 |
Price($) | Vol. | No. |
---|---|---|
0.039 | 865746 | 2 |
0.040 | 577500 | 3 |
0.041 | 350000 | 1 |
0.042 | 138405 | 2 |
0.043 | 196890 | 3 |
Last trade - 15.29pm 04/07/2025 (20 minute delay) ? |
Featured News
IPD (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online